New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Johnson & Johnson

JNJ

Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

270.19 3.09 +1.16%
Market cap
$650.7B
P/E
40.5×
Fwd P/E FY26e
41.8×
Dividend yield
1.98%
F-score
3/9
ROIC
11.1%
Net debt / EBITDA
0.5×
Payout ratio
0.8×

Johnson & Johnson 8-K filed Oct 14, 2025

Period ended Oct 14, 2025 · Filed · accepted 7:22 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release